Key result
Anti-citrullinated protein antibodies (ACPAs) serve as specific serological markers for rheumatoid arthritis that can predict disease severity and appear years before clinical onset.
May support early ACPA monitoring in at-risk individuals; leaves open optimal preventive strategies in preclinical RA.
Disease-specific autoantibodies directed against post-translation citrullinated proteins/peptides (ACPAs) are specific serological markers for rheumatoid arthritis (RA) and have been accepted as one of the classification criteria for the disease. Beyond diagnosis these autoantibodies have also been shown also to predict disease severity. These autoantibodies can be detected several years prior to the clinical onset of RA, with increasing titers overtime, as disease onset is established. Citrullination is a post-translational modification of proteins in which arginine is converted into citrulline, an unnatural amino acid which is not encoded by DNA. The reaction is catalyzed by calcium-dependent peptidyl arginine deiminase (PAD). Citrullinated proteins have been detected in the synovial membranes and synovial
No takes yet. Share an insight, caveat, or question.
Gertel et al. (2015) conducted a review in Rheumatoid arthritis. Tolerogenic citrullinated peptide was evaluated. Anti-citrullinated protein antibodies (ACPAs) serve as specific serological markers for rheumatoid arthritis that can predict disease severity and appear years before clinical onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: